ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
35 announcements with these filters
Parmax Pharma scheduled a board meeting for November 13, 2026 to approve unaudited quarterly and half-year results and shift its registered office. The filing is a prior intimation with no figures.
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Parmax Pharma Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Parmax Pharma Ltd announced the resignation of Mr. Nikhil Uchat as an Independent Director of the Company, effective October 08, 2026.
Parmax Pharma Ltd conducted its 32nd Annual General Meeting on September 29, 2026, covering routine business including financial statement adoption and board appointments.
Parmax Pharma reported a major fire incident at its Rajkot plant on September 28, 2026. Two employees were injured, and the company is currently assessing the financial damage.
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.
Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.
Parmax Pharma allotted 31.37 lakh equity shares at Rs. 36.50 each and 21.45 lakh convertible warrants to various non-promoter allottees on a preferential basis.
Parmax Pharma announced the reclassification of its promoters following an open offer and share purchase agreement. Existing promoters will be reclassified under the public category.
Fedex Securities issued a post-offer advertisement for the open offer of Parmax Pharma Limited. The offer involved acquiring 26% stake at ₹42.80 per share.
Parmax Pharma received BSE's 'In-Principle' approval for a preferential issuance of 31,37,586 equity shares and 21,45,145 warrants at Rs. 36.50 per unit.
Promoters Alkesh Mahasukhlal Gopani and others sold their entire 30.81% stake in Parmax Pharma Ltd. The off-market sale of 11,52,450 shares concluded on August 13, 2026.
Sunil Chinubhai Shah and others acquired 11,52,450 shares (30.81%) of Parmax Pharma Limited. This off-market purchase via a Share Purchase Agreement increases their collective holding to 58.01%.
Parmax Pharma Limited announced the appointment of Dhiren Shah and Sunil Shah as Directors. Additionally, Ms. Salma Thobhani resigned as a Non-Executive Non-Independent Director.
Parmax Pharma Ltd reported revenue from operations of ₹8.2 Cr (+331.6% YoY) and net profit of ₹2.2 Cr for Q1 FY27.
Sunil Chinubhai Shah and others acquired 11,52,450 equity shares (30.81%) of Parmax Pharma Limited. This SPA-based acquisition increases the promoter group stake to 58.01%.
Parmax Pharma Ltd has scheduled a board meeting for August 14, 2026. The meeting's agenda includes the approval of unaudited financial results for the June quarter.
Fedex Securities submitted a Letter of Offer for Parmax Pharma Ltd. Acquirers intend to buy 23,46,250 equity shares (26% stake) from public shareholders.
Parmax Pharma Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as required by regulatory norms.
Parmax Pharma Ltd increased authorized capital by Rs. 4 Crore to Rs. 10 Crore. New Articles of Association were adopted to align with the Companies Act, 2013.
Parmax Pharma Ltd held its 2nd EGM on July 2, 2026, to approve capital restructuring. Key resolutions included increasing authorized share capital and issuing preferential equity and warrants.
Parmax Pharma convened an EGM for July 02, 2026, to approve a ₹19.28 Crore preferential issue. The move supports working capital and general corporate purposes.
Parmax Pharma announced a Share Purchase Agreement for a change in control. The deal includes a ₹19.28 Crore preferential issuance of shares and warrants.
Acquirers launched a ₹10.04 Crore open offer for a 26% stake in Parmax Pharma Limited. This mandatory bid follows significant equity acquisitions through share purchase and preferential allotments.
Parmax Pharma's board approved a ₹19.28 Crore preferential issue of equity shares and warrants. The capital raise targets non-promoter investors to strengthen the company's financial position.
Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.
Parmax Pharma Limited filed the scrutinizer's report for its Extra Ordinary General Meeting held on May 27, 2025. Shareholders approved key director appointments and re-appointments via remote e-voting.